JP2013224953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013224953A5 JP2013224953A5 JP2013133614A JP2013133614A JP2013224953A5 JP 2013224953 A5 JP2013224953 A5 JP 2013224953A5 JP 2013133614 A JP2013133614 A JP 2013133614A JP 2013133614 A JP2013133614 A JP 2013133614A JP 2013224953 A5 JP2013224953 A5 JP 2013224953A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- use according
- cells
- nucleoside
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 63
- 206010028980 Neoplasm Diseases 0.000 claims 47
- 201000011510 cancer Diseases 0.000 claims 47
- 239000002777 nucleoside Substances 0.000 claims 22
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 18
- 229940127073 nucleoside analogue Drugs 0.000 claims 17
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 16
- 206010006187 Breast cancer Diseases 0.000 claims 12
- 208000026310 Breast neoplasm Diseases 0.000 claims 12
- 206010033128 Ovarian cancer Diseases 0.000 claims 12
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 12
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 11
- 229960004150 aciclovir Drugs 0.000 claims 11
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 210000003411 telomere Anatomy 0.000 claims 11
- 102000055501 telomere Human genes 0.000 claims 11
- 108091035539 telomere Proteins 0.000 claims 11
- 206010046766 uterine cancer Diseases 0.000 claims 11
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 10
- 230000037060 G2 phase arrest Effects 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 9
- 230000006907 apoptotic process Effects 0.000 claims 9
- 206010017758 gastric cancer Diseases 0.000 claims 9
- 238000004904 shortening Methods 0.000 claims 9
- 201000011549 stomach cancer Diseases 0.000 claims 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 8
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims 8
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 8
- 201000005202 lung cancer Diseases 0.000 claims 8
- 208000020816 lung neoplasm Diseases 0.000 claims 8
- 206010005949 Bone cancer Diseases 0.000 claims 7
- 208000018084 Bone neoplasm Diseases 0.000 claims 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 7
- 206010060862 Prostate cancer Diseases 0.000 claims 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 7
- 208000016624 Retinal neoplasm Diseases 0.000 claims 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims 7
- 108010017842 Telomerase Proteins 0.000 claims 7
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 7
- 206010057644 Testis cancer Diseases 0.000 claims 7
- 208000029742 colonic neoplasm Diseases 0.000 claims 7
- 201000004101 esophageal cancer Diseases 0.000 claims 7
- 208000032839 leukemia Diseases 0.000 claims 7
- 201000007270 liver cancer Diseases 0.000 claims 7
- 208000014018 liver neoplasm Diseases 0.000 claims 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 7
- 201000002528 pancreatic cancer Diseases 0.000 claims 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 7
- 201000008933 retinal cancer Diseases 0.000 claims 7
- 201000000849 skin cancer Diseases 0.000 claims 7
- 201000003120 testicular cancer Diseases 0.000 claims 7
- -1 acyclic nucleoside Chemical class 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- 230000000750 progressive effect Effects 0.000 claims 6
- NZVORGQIEFTOQZ-UHFFFAOYSA-N 9-[2-(phosphonomethoxy)ethyl]guanine Chemical compound N1C(N)=NC(=O)C2=C1N(CCOCP(O)(O)=O)C=N2 NZVORGQIEFTOQZ-UHFFFAOYSA-N 0.000 claims 4
- FRPXSOOHWNMLPH-LURJTMIESA-N [(2s)-1-(6-aminopurin-9-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid Chemical compound NC1=NC=NC2=C1N=CN2C[C@@H](CO)OCP(O)(O)=O FRPXSOOHWNMLPH-LURJTMIESA-N 0.000 claims 4
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- 229960001179 penciclovir Drugs 0.000 claims 4
- XHXFQGAZAVKMFF-UHFFFAOYSA-N 2-(2,6-diaminopurin-9-yl)ethoxymethylphosphonic acid Chemical compound NC1=NC(N)=C2N=CN(CCOCP(O)(O)=O)C2=N1 XHXFQGAZAVKMFF-UHFFFAOYSA-N 0.000 claims 2
- PDHWTDJKKJYOGD-UHFFFAOYSA-N 2-[2-amino-6-(cyclopropylamino)purin-9-yl]ethoxymethylphosphonic acid Chemical compound C=12N=CN(CCOCP(O)(O)=O)C2=NC(N)=NC=1NC1CC1 PDHWTDJKKJYOGD-UHFFFAOYSA-N 0.000 claims 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- SUPKOOSCJHTBAH-UHFFFAOYSA-N adefovir Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 claims 2
- 229960001997 adefovir Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229960004396 famciclovir Drugs 0.000 claims 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 229940093257 valacyclovir Drugs 0.000 claims 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66510505P | 2005-03-25 | 2005-03-25 | |
| US60/665,105 | 2005-03-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503271A Division JP2008536822A (ja) | 2005-03-25 | 2006-03-27 | テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013224953A JP2013224953A (ja) | 2013-10-31 |
| JP2013224953A5 true JP2013224953A5 (enExample) | 2014-05-22 |
Family
ID=37053967
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503271A Pending JP2008536822A (ja) | 2005-03-25 | 2006-03-27 | テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療 |
| JP2013133614A Pending JP2013224953A (ja) | 2005-03-25 | 2013-06-26 | テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503271A Pending JP2008536822A (ja) | 2005-03-25 | 2006-03-27 | テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US7741296B2 (enExample) |
| EP (1) | EP1868615A4 (enExample) |
| JP (2) | JP2008536822A (enExample) |
| CN (2) | CN101193643A (enExample) |
| CA (1) | CA2602562C (enExample) |
| WO (1) | WO2006104975A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050113324A1 (en) * | 2003-01-15 | 2005-05-26 | Bondarev Igor E. | Modulation of line-1 reverse transcriptase |
| EP1885370A4 (en) * | 2005-05-18 | 2012-07-25 | Alt Solutions Inc | PHARMACOLOGICAL MODULATION OF THE TELOMER LENGTH OF CANCER CELLS FOR THE PREVENTION AND TREATMENT OF CANCER |
| EP2001488A4 (en) * | 2006-03-14 | 2009-11-25 | Alt Solutions Inc | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES |
| US9593137B2 (en) | 2011-12-22 | 2017-03-14 | Geron Corporation | Guanine analogs as telomerase substrates and telomere length affectors |
| CN102660650A (zh) * | 2012-05-25 | 2012-09-12 | 云南路易斯中药现代化工程技术研究中心 | 一种实时定量pcr测量样品中染色体端粒平均长度的绝对值的试剂盒及应用 |
| ES2972330T3 (es) * | 2012-11-30 | 2024-06-12 | Geron Corp | Marcadores diagnósticos para el tratamiento de trastornos proliferativos celulares con inhibidores de la telomerasa |
| US9795242B2 (en) | 2013-02-14 | 2017-10-24 | Cirkul, Inc. | Additive delivery systems and containers |
| US10888826B2 (en) | 2014-11-21 | 2021-01-12 | Cirkul, Inc. | Adjustable additive cartridge systems and methods |
| WO2016081925A1 (en) | 2014-11-21 | 2016-05-26 | Samsara Bottle System, Inc. | Adjustable additive cartridge systems |
| EP3753563A1 (en) * | 2019-06-20 | 2020-12-23 | Helmholtz-Zentrum für Infektionsforschung GmbH | Anti-herpesvirus guanosine analogue for the inhibition of basal autophagy |
| CN112168829B (zh) * | 2020-09-24 | 2022-02-15 | 华南理工大学 | 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585363A (en) * | 1987-05-05 | 1996-12-17 | City Of Hope | Circumvention of human tumor drug resistance |
| US5166140A (en) * | 1987-05-05 | 1992-11-24 | City Of Hope | Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy |
| US5489508A (en) * | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5654286A (en) * | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
| US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5981507A (en) * | 1995-12-14 | 1999-11-09 | Advanced Magnetics, Inc. | Polymeric carriers linked to nucleotide analogues via a phosphoramide bond |
| GB9601544D0 (en) * | 1996-01-26 | 1996-03-27 | Smithkline Beecham Plc | Pharmaceuticals |
| WO2000078941A2 (en) * | 1999-06-23 | 2000-12-28 | University Of Vermont And State Agricultural College | Methods and products for manipulating uncoupling protein expression |
| US20050113324A1 (en) * | 2003-01-15 | 2005-05-26 | Bondarev Igor E. | Modulation of line-1 reverse transcriptase |
-
2006
- 2006-03-27 JP JP2008503271A patent/JP2008536822A/ja active Pending
- 2006-03-27 CA CA2602562A patent/CA2602562C/en not_active Expired - Fee Related
- 2006-03-27 EP EP06748718A patent/EP1868615A4/en not_active Withdrawn
- 2006-03-27 US US11/886,446 patent/US7741296B2/en not_active Expired - Fee Related
- 2006-03-27 CN CNA200680015221XA patent/CN101193643A/zh active Pending
- 2006-03-27 CN CN201510092529.5A patent/CN104997783A/zh active Pending
- 2006-03-27 WO PCT/US2006/011027 patent/WO2006104975A2/en not_active Ceased
-
2010
- 2010-05-12 US US12/662,939 patent/US8097595B2/en not_active Expired - Fee Related
-
2012
- 2012-01-06 US US13/344,651 patent/US8580753B2/en not_active Expired - Fee Related
-
2013
- 2013-06-26 JP JP2013133614A patent/JP2013224953A/ja active Pending
- 2013-11-11 US US14/076,518 patent/US20140065072A1/en not_active Abandoned
-
2015
- 2015-09-17 US US14/856,122 patent/US20160000937A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013224953A5 (enExample) | ||
| WO2013167743A1 (en) | Use of compounds for the treatment of pain | |
| ES2251168T3 (es) | Agente antiviral en combinacion con radioterapia para el tratamiento del cancer. | |
| US20150290235A1 (en) | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections | |
| ES2982897T3 (es) | Uso del inhibidor de la telomerasa imetelstat para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas | |
| JP2019527230A5 (enExample) | ||
| EA019869B1 (ru) | Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения | |
| HK1200716A1 (zh) | 使用胞苷類似物的口服製劑治療癌症的方法 | |
| Ray et al. | Application of kinase bypass strategies to nucleoside antivirals | |
| RU2018138976A (ru) | Лечение рака головного мозга | |
| CN110769837A (zh) | 与五氮杂大环状环配合物的联合癌症免疫疗法 | |
| JP2014144962A5 (enExample) | ||
| De Clercq | The Holý Trinity: the acyclic nucleoside phosphonates | |
| JP2009530295A5 (enExample) | ||
| JP2010509205A5 (enExample) | ||
| JP2007518815A5 (enExample) | ||
| CA2644297A1 (en) | Prevention and treatment of cancer and other diseases | |
| US7572800B2 (en) | Combination therapy to treat hepatitis B virus | |
| US20240199662A1 (en) | Prodrugs of l-bhdu and methods of treating viral infections | |
| CA2868024A1 (en) | Methods of treating cancer using aurora kinase inhibitors | |
| CN102905709B (zh) | 同时、单独或相继用于治疗和/或预防和/或减轻癌症的egfr抑制剂和抗病毒剂 | |
| US20150110864A1 (en) | Novel antitumor agent comprising combination of three agents | |
| KR20240004543A (ko) | 혈액암을 치료하는 방법 | |
| De Clercq | </i> Obituary<//i> The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonin HolATIN SMALL LETTER Y WITH ACUTE, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death | |
| Rowe et al. | l-β-1-(5-Bromovinyl-2-hydroxymethyl-1, 3-dioxolanyl) Uracil (l-Bhdu) Prevents Varicella-Zoster Virus Replication in Fibroblasts, Skin Organ Culture, and Scid-Hu Mice with Human Skin Xenografts |